Longitudinal study in HIV/HCV-coinfected HAART-naive patients and role of HCV genotype

被引:9
作者
Caudai, C
Pianese, M
Zacchini, F
Toti, M
Zazzi, M
Valensin, PE
机构
[1] Univ Siena, Policlin Le Scotte, Dept Biol Mol, Virol Sect, I-53100 Siena, Italy
[2] Mater Misericordiae Univ Hosp, Div Infect Dis, Grosseto, Italy
关键词
HCV/HIV coinfection; HAART; HCV-RNA; HIV-RNA; HCV genotype;
D O I
10.1016/j.jcv.2004.05.005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
To evaluate the impact of highly active antiretroviral therapy (HAART) on the course of hepatitis C (HCV) infection, we studied the biological and virological characteristics of 23 HCV/HIV-coinfected HAART-naive patients. The HCV genotype, HCV and HIV viral loads, serum alanine aminotransferase, CD4(+) and CD8(+) cell/mm(3) were determined at baseline, I month, 6 months and 12 months after initiation of HAART. Results were analyzed both in terms of total population and of HCV genotype. The study of the total population suggests that this therapy did not determine a significant alteration of HCV viremia and levels of ALT, while a significant decrease in HIV viremia (-1.7 log(10) at one year from the start of HAART) and increase in CD4(+) counts was observed (P < 0.005). The biological and virological parameters of HCV/HIV coinfection differed according to the HCV genotype. In particular, only genotype 4 showed a significant inverse correlation between HCV and HIV viral loads. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:151 / 155
页数:5
相关论文
共 33 条
  • [1] Antibody testing and RT-PCR results in hepatitis C virus (HCV) infection: HCV-RNA detection in PBMC of plasma viremia-negative HCV-seropositive persons
    Caudai, C
    Padula, MG
    Bastianoni, I
    Valensin, PE
    Shyamala, V
    Han, J
    Boggiano, CA
    Almi, P
    [J]. INFECTION, 1998, 26 (03) : 151 - 154
  • [2] CHAMOT E, 1992, AIDS, V6, P430, DOI 10.1097/00002030-199204000-00013
  • [3] CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
  • [4] Role of endogenous interferon in hepatitis C virus (HCV) infection and in coinfection by HIV and HCV
    Cribier, B
    Schmitt, C
    Rey, D
    Lang, JM
    Kirn, A
    StollKeller, F
    [J]. RESEARCH IN VIROLOGY, 1996, 147 (05): : 263 - 266
  • [5] Dieterich Douglas T., 1999, American Journal of Medicine, V107, p79S
  • [6] Hepatitis C and human immunodeficiency virus coinfections
    Dodig, M
    Tavill, AS
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2001, 33 (05) : 367 - 374
  • [7] Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection
    Fialaire, P
    Payan, C
    Chennebault, JM
    Loison, J
    Pichard, E
    Lunel, P
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02) : 574 - 575
  • [8] Forns X, 1999, Clin Liver Dis, V3, P693, DOI 10.1016/S1089-3261(05)70234-8
  • [9] Assessment of spontaneous fluctuations of viral load in untreated patients with chronic hepatitis C by two standardized quantitation methods:: Branched DNA and Amplicor monitor
    Halfon, P
    Bourlière, M
    Halimi, G
    Khiri, H
    Bertezene, P
    Portal, I
    Bota-Fridlund, D
    Gauthier, AP
    Jullien, M
    Feryn, JM
    Gerolami, V
    Cartouzou, G
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (07) : 2073 - 2075
  • [10] Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by Quantiplex HCV RNA assay versions 1 and 2, Roche monitor assay, and an in-house limiting dilution method
    Hawkins, A
    Davidson, F
    Simmonds, P
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (01) : 187 - 192